Global Imaging Agents Market

  • September 2014
  • -
  • Global Industry Analysts
  • -
  • 343 pages

This report analyzes the worldwide markets for Imaging Agents in US$ by the following Product Segments: Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 52 companies including many key and niche players such as -

Bayer Healthcare Pharmaceuticals
Bracco Diagnostics, Inc.
Daiichi Sankyo Company Limited
Eisai Co., Ltd.
Eli Lilly and Company

Table Of Contents




I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3
Contrast Media I-3
X-Ray Contrast Media I-3
Magnetic Resonance Imaging (MRI) Contrast Media I-3
Ultrasound Contrast Media I-4
Diagnostic Radiopharmaceuticals I-4


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Imaging Agents: A Quick Primer II-1
Market Scenario: Recession and the Road Ahead II-2
Current and Future Analysis II-2
Analysis by Region II-3
United States: Holds the Largest Share II-3
Developing Countries: Potentially Lucrative Market II-3
Analysis by Segment II-4
Contrast Media: Giving Way to Contemporary Offshoots II-4
Diagnostic Radiopharmaceuticals to Outdo Contrast Media II-5
Growth Drivers II-6
Growth Inhibitors II-7
Nuclear Medicine: A Potential Growth Avenue for Dx
Radiopharmaceuticals II-8
Select PET and SPECT Radioisotopes Used in Nuclear Medicine II-8
Select Cardiology and Oncology Radiopharmaceuticals II-9
Rising Incidence of Cancer - A Major Growth Driver II-9
World Cancer Statistics - Incidence and Mortality Data II-9
Table 1: World Cancer Incidence by Geographic Region
(2012): Number of New Cancer Cases Reported in Thousands
for Asia-Oceania, Europe, North America, Latin America and
the Caribbean, and Africa (includes corresponding
Graph/Chart) II-9

Table 2: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer-Related Deaths in Thousands
for Asia-Oceania, Europe, North America, Latin America and
the Caribbean, and Africa (includes corresponding
Graph/Chart) II-10
Improving Healthcare Expenditure to Foster Growth II-10
Table 3: Per-Capita Healthcare Expenditure in Select Regions
(2013) (includes corresponding Graph/Chart) II-11

Table 4: Top 20 Countries with the Highest Healthcare
Spending as a Percentage of GDP: 2012 (includes corresponding
Graph/Chart) II-11

Table 5: Top 10 Countries with Highest Government Spending on
Health Care (includes corresponding Graph/Chart) II-12

Table 6: Top 10 Countries with Highest Private Spending on
Health Care (includes corresponding Graph/Chart) II-12
Ageing Population - A Vital Demography II-13
Table 7: Global Population Statistics for the 65+ Age Group
(Male and Female) for Major Countries/Regions: 2013E (includes
corresponding Graph/Chart) II-14

Table 8: Percentage of Population Aged 65 and Above in
Europe, US, and Japan (1960-2030) (includes corresponding
Graph/Chart) II-15

Table 9: Elderly Population (65+ Years) as a Percentage of
the Total Population: 2025 (includes corresponding
Graph/Chart) II-15
A Peek Into Pricing Dynamics II-15
A Synoptic Overview II-15
Pros and Cons II-16
Positive Factors Driving Prices II-16
Negative Factors Bearing Down on Prices II-16
Reimbursements II-16
Europe II-17
United States II-17

2. A SEGMENTAL REVIEW II-18
Contrast Media II-18
Popular Brands of Contrast Agents II-18
X-ray Contrast Media II-19
MRI Contrast Media II-20
Market Scenario II-20
List of FDA Approved Gadolinium-Based Contrast Agents (
GBCA) for CNS MRI II-20
List of EMA Approved Gd Chelated Contrast Agents II-21
Ultrasound Contrast Media II-21
Market Overview II-21
Diagnostic Radiopharmaceuticals II-22
Market Overview II-22
Commonly Used Diagnostic Radiopharmaceutical Agents II-22
Major Isotopes and their Diagnostic Applications II-23
List of Select FDA-Approved Diagnostic Radiopharmaceuticals II-24
New Imaging Agent for Radiopharmaceutical Scans II-25
Immunoconjugates II-25
Market Overview II-25

3. MARKET TRENDS and ISSUES II-26
Expansion of Molecular Imaging Platform is Key to Future Growth II-26
Growing Interest in Image Guided Surgery Offers New Opportunities II-26
Fluorescence Optical Imaging - Opens New Avenues II-26
Coronary CT Angiography Opens Up Opportunities for Contrast
Agents II-27
List of Iodine-Containing Contrast Agents for Coronary CT
Angiography II-27
Targeted Imaging - A Game Changer in the Making? II-27
Clinical Acceptance of MRI Systems on Rise II-28
Nanomaterials Taking the Center Stage II-29
Gadolinium Coated Nanoparticles - A Promising Imaging Agent II-29
Rise in Use of Gold Nanoparticles in X-Ray Imaging Applications II-30
Imaging Agents Make a Welcome Impact in the Field of
Alzheimer’s Disease II-30
List of FDA Approved Alzheimer's Diagnostic Imaging Agents II-32
Contrast-Enhanced Tomosynthesis Expands Opportunities II-32
Hyperpolarized Gases as Contrast Agents II-32
Multi-Modal Imaging: Combating Contrast Medium Inconsistencies II-32
Falling Prices Turn on the Heat II-33
Ultrasound Contrast Agents in Diagnosis of Kidney Ailments II-33
FDA Mandates Black Box Warning Label for Gadolinium-Based MRI
Contrast Agents II-33
PET: A Prime Growth Driver for Diagnostic Radiopharmaceuticals II-34
Innovative Radiotracers to Boost Cardiac Applications for
SPECT and PET Modalities II-34
Global CVD Stats II-36
Table 10: Global Estimated Fatalities by Heart Conditions -
Percentage Share Breakdown for Ischemic Heart Disease,
Stroke, CVD, and Others (includes corresponding Graph/Chart) II-36

Table 11: Projected Fatalities in Low Income Countries by
Disease (2015 and 2030): Percentage Share Breakdown of Number
of Deaths for CVD; Cancer; Injury; HIV, TB and Malaria;
Malnutrition; and Others (includes corresponding Graph/Chart) II-36

Table 12: Projected Fatalities in Mid Income Countries by
Disease (2015 and 2030): Percentage Share Breakdown of Number
of Deaths for CVD; Cancer; Injury; HIV, TB and Malaria;
Malnutrition; and Others (includes corresponding Graph/Chart) II-37

Table 13: Projected Fatalities in High Income Countries by
Disease (2015 and 2030): Percentage Share Breakdown of Number
of Deaths for CVD, Cancer, Injury and Others (includes
corresponding Graph/Chart) II-37

Table 14: Estimated Annual Medical Cost (US$ Billions) for
Coronary Heart Disease (2015, 2020 and 2025) (includes
corresponding Graph/Chart) II-38
Opportunities on Rise for Fluorine-Based Myocardial Perfusion
Agents II-38
Mobile Devices - Future of Diagnostic Imaging? II-38
Global Technetium Shortage Eased II-39
Unfounded Fears of Radiation Exposure: A Major Concern for
Nuclear Diagnostics II-39

4. COMPETITION II-40
Market Structure II-40
Market Participants II-40
Key Players in the MRI Market II-41
Ultrasound Imaging Agents Market II-41
Diagnostic Radiopharmaceuticals II-41
Table 15: Worldwide Imaging Agents Market (2013): Percentage
Breakdown of Value Sales for Leading Players - Bayer
Schering Pharmaceuticals, Bracco, Covidien/Mallinckrodt, GE
Healthcare, and Others (includes corresponding Graph/Chart) II-42

Table 16: MRI Contrast Media Market Worldwide (2013):
Percentage Breakdown of Sales for Bayer Schering
Pharmaceuticals, Bracco, Covidien/Mallinckrodt, GE
Healthcare, and Others (includes corresponding Graph/Chart) II-42

Table 17: Radiopharmaceutical Contrast Media Market
Worldwide (2009): Percentage Breakdown of Sales for GE
Healthcare, Bristol-Myers Squibb, Covidien/Mallinckrodt, MDS
Nordion and Others (includes corresponding Graph/Chart) II-42

5. GLOBAL MEDICAL IMAGING MARKET - AN OVERVIEW II-43
Medical Imaging - Changing the Landscape of Clinical Diagnosis II-43
Table 18: Global Medical Imaging Equipment Installed Base
(2013): Percentage Share Breakdown of Volume Installations
for X-ray, Ultrasound, Magnetic Resonance, Computed
Tomography, and Nuclear Medicine/PET by Country/Region
(includes corresponding Graph/Chart) II-44
Comparison of Modalities by Various Imaging Systems II-44
Table 19: Cost Comparison of Different Imaging Modalities II-45
Medical Imaging Industry under the Impact of Economic Downturn II-45
Archaic X-Ray Imaging Modalities Paving Way for Digital X-Rays II-45
Ultrasound Holds its Fort in the Medical Imaging Market II-46
Technological Advancements Favor MRI Market II-47
Table 20: Global MRI Usage by Application Area (2012)
(includes corresponding Graph/Chart) II-49
Comparison of MRI against Other Imaging Modalities II-49
Nuclear Medicine Imaging Equipment Presents Lucrative Growth
Opportunities II-49
Table 21: Worldwide Installed Base of Nuclear Imaging Devices
by Modality (2013) Percentage Share Breakdown of Number of
Installations for SPECT and PET (includes corresponding
Graph/Chart) II-50
Hybrid Imaging to Herald a New Era of Diagnosis II-50
Hybrid PET/MRI Systems: A New Fusion II-51
Price Sensitivity and Competition from Alternatives Limit
Market Potential II-52
Unfounded Fears of Radiation Exposure Hinder Growth II-52
Bottlenecks in Developing Markets II-52
Use of Contrast Agents in Other Imaging Modalities II-53
Fluoroscopy II-53
Computed Tomography II-53
Future Growth Prospects for Medical Imaging Equipment Market II-53

6. PRODUCT OVERVIEW II-55
Contrast Agents II-55
Contrast Media: How Do They Function? II-55
Where Are They Used ? II-56
Evolution of Contrast Media: A Profile II-56
Bismuth Nitrate: Beginning of Contrast Agents II-56
Imaging Agents: Significant Developments in the Last Fifty Years II-57
Schering Develops First Intravenous Contrast Agent II-57
MRI: Creating a New Era for Contrast Agents II-57
A Peek into the Finer Points of Differences Among Contrast Media II-57
Second Generation Non-Ionic Contrast Agents: An Introduction II-58
Choice of the Contrast Medium: A Weighty Decision II-58
Factors affecting choice of Imaging Agents II-58
Taxonomy II-58
Types of Contrast Media II-59
X-Ray Contrast Medium II-59
Table 22: Comparative Analysis of Structure of Non-ionic and
ionic X-ray Contrast Media II-60
MRI Contrast Medium II-60
Role of Contrast Enhancement in MR Angiography (MRA) II-61
MRI Contrast Agents for the Liver II-61
Ultrasound Contrast Medium II-62
Ultrasonographic Contrast Media: What Are They? II-62
Ultrasound Contrast Enhancement in Cardiology II-63
Functionalities of Vascular Ultrasound Contrast Agents II-63
Diagnostic Radiopharmaceuticals II-64
A Delineate of Diagnostic Radiopharmaceuticals II-64
Diagnostic Radiopharmaceuticals: A Technical Run-Through II-65
Applications II-65
Classification II-66
Cardiology Diagnostics II-66
Non-cardiology Diagnostics II-66
Molecular Imaging Modalities in Radiopharmaceutical
Diagnostics II-66
Planar Imaging II-66
Positron Emission Tomography (PET) II-67
Applications of PET II-67
Commonly used Radioisotopes in PET Scans II-68
Major PET Isotopes and their Applications II-68
Single Photon Emission Computed Tomography (SPECT) II-68
Applications of SPECT II-69
Commonly used Radioisotopes in SPECT Scans II-69

7. TECHNOLOGY DYNAMICS II-70
Proprietary Technologies Making In-Roads II-70
Advanced Magnetics’ Proprietary Colloidal Superparamagnetic
Particle Technology II-70
Enzon’s Single Chain Antigen-Binding Technology II-70
Immunomedics’ Antibody Technology II-70
NeoRx’s “Painting the Target” Technology II-71
Gas Encapsulation Technology for Ultrasound Contrast Media II-71
Pharmacyclics’ Texaphyrin Technology II-72
Regulatory Bodies II-72
Entry Barriers II-72
Research Driven Markets II-72
Highly Competitive Market II-72
Economies of Scale II-73
Substitutes in Agents Manufacturing II-73
New X-ray Diagnostic Agents II-73
Amide-based Macrocyclic Ligands - Potential MRI Agents II-73
Gadolinium (III) Complexes - Potential MRI Contrast Agents II-73
Metal-Containing Compounds Act As Potential Contrast Agents II-73
Therapeutic Applications II-73
Diagnostic Applications II-73
Magnetic Gels as Potential MRI Contrast Agents II-74
PFCs as Diagnostic Contrast Agents II-74
Saline Flushes To Help Ensure Accurate Delivery of Contrast
Agents II-74

8. PRODUCT LAUNCHES/APPROVALS/ CLINICAL TRIALS II-75
GE Introduces Vizamyl Alzheimer's imaging Agent II-75
Navidea Biopharmaceuticals Obtains FDA Approval for Lymphoseek
Injection for New Indication II-75
Bayer Obtain FDA Approval for Gadavist for Breast Cancer
Evaluation II-75
GE Healthcare Gets Norwegian Medicines Agency Approval for
Sonazoidâ„¢ to Detect Focal Liver Lesions II-75
ImaginAb Announces Initial Phase I/IIa Results for 89Zr-Df-
IAB2M Prostate Imaging Agent II-75
Primal Imaging Receives FDA Approval for Neuraceq PET Imaging
Agent II-75
NanoHybrids Introduces Premium Product Line of Imaging
Contrast Agents II-76
CMC Contrast AB Obtains Orphan Drug Designation from the US
FDA for CMC-001 II-76
GE Healthcare Obtains FDA Approval for its Oslo Plant to
Manufacture Optison Heart Imaging Agent II-76
GE Healthcare Gets FDA Approval for Vizamyl Alzheimer's
Imaging Agent II-76
GeccoDots Launches New Contrast Agent II-76
Navidea Biopharmaceuticals Signs Agreement with Nordion II-76
Navidea Biopharmaceuticals Launches Lymphoseek® II-77
GE Healthcare Gets Expanded FDA Approval for AdreView II-77
Guerbet Obtains FDA Approval for Dotarem MRI Contrast Agent II-77
PerkinElmer Introduces GFR-Vivo 680 II-77
Navidea Obtains FDA Approval for Lymphoseek® Injection II-77
Navidea Signs Agreement with Maimonides Medical Center to
Collaborate on Clinical Trial Utilizing Lymphoseek® Injection
in Colorectal Cancer II-77
Molecular Insight Pharmaceuticals Commences Phase II Clinical
Trial with Prostate Cancer Molecular Imaging Agent II-78
Navidea Launches Phase II Clinical Trial with NAV4694 II-78
FDA Approves Production and Use of Choline C 11 Injection to
Detect Recurrent Prostate Cancer II-78
PerkinElmer Introduces HER2Senseâ„¢ Preclinical Imaging Agent II-78

9. RECENT INDUSTRY ACTIVITY II-79
ImaginAb and Duke-NUS Partner to Develop in vivo Molecular
Imaging Agents II-79
AC Immune and Piramal Imaging Strike Deal to Develop
Alzheimer's Imaging Agent II-79
Blue Earth Diagnostics Commences Operations II-79
Enlyton Bags SBIR Contract from NCI for Pre-Clinical
Development of Tumor Imaging Agent II-79
Guerbet Obtains FDA Approval for Lipiodol Contrast Agent
Manufacturing Plant II-79
Integrated Diagnostics Launches InDi Molecular II-79
Endocyte Signs Licensing Agreement with Endocyte for
etarfolatide Cancer Diagnostic Imaging Agent II-80
Siemens’ PETNET Solutions Signs Agreement with Navidea
Biopharmaceuticals II-80
Covidien to Spin-Off Mallinckrodt II-80
Eli Lilly to Acquire two Alzheimer's Imaging Agents from Siemens II-80
Siemens PETNET Solutions Expands Manufacturing and
Distribution of Amyvid II-80
Jazz Pharmaceuticals Acquires EUSA Pharma II-80

10. FOCUS ON SELECT PLAYERS II-81
Bayer Healthcare Pharmaceuticals (Germany) II-81
Bracco Diagnostics, Inc. (US) II-81
Daiichi Sankyo Company Limited (Japan) II-82
Eisai Co., Ltd. (Japan) II-82
Eli Lilly and Company (US) II-83
EUSA Pharma (Europe) Ltd. (UK) II-83
GE Healthcare (UK) II-84
Guerbet Group (France) II-85
Lantheus Medical Imaging Inc (US) II-85
Mallinckrodt Pharmaceuticals (Ireland) II-86

11. GLOBAL MARKET PERSPECTIVE II-87
Table 23: World Recent Past, Current and Future Analysis for
Imaging Agents by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-87

Table 24: World Historic Review for Imaging Agents by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) II-88

Table 25: World 15-Year Perspective for Imaging Agents by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) II-89

Table 26: World Recent Past, Current and Future Analysis for
Contrast Media by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-90

Table 27: World Historic Review for Contrast Media by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) II-91

Table 28: World 15-Year Perspective for Contrast Media by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) II-92

Table 29: World Recent Past, Current and Future Analysis for
Contrast Media by Product Segment - X-Ray, MRI and Ultrasound
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-93

Table 30: World Historic Review for Contrast Media by Product
Segment - X-Ray, MRI and Ultrasound Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) II-94

Table 31: World 15-Year Perspective for Contrast Media by
Product Segment - Percentage Breakdown of Dollar Sales for
X-Ray, MRI and Ultrasound Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) II-95

Table 32: World Recent Past, Current and Future Analysis for
X-Ray Contrast Media by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-96

Table 33: World Historic Review for X-ray Contrast Media by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) II-97

Table 34: World 15-Year Perspective for X-Ray Contrast Media
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) II-98

Table 35: World Recent Past, Current and Future Analysis for MRI
Contrast Media by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-99

Table 36: World Historic Review for MRI Contrast Media by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) II-100

Table 37: World 15-Year Perspective for MRI Contrast Media by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) II-101

Table 38: World Recent Past, Current and Future Analysis for
Ultrasound Contrast Media by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Middle East and
Latin America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) II-102

Table 39: World Historic Review for Ultrasound Contrast Media
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) II-103

Table 40: World 15-Year Perspective for Ultrasound Contrast
Media by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Middle East and Latin America Markets for Years 2006,
2014 and 2020 (includes corresponding Graph/Chart) II-104

Table 41: World Recent Past, Current and Future Analysis for
Diagnostic Radiopharmaceuticals by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle
East and Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2013 through
2020 (includes corresponding Graph/Chart) II-105

Table 42: World Historic Review for Diagnostic
Radiopharmaceuticals by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) II-106

Table 43: World 15-Year Perspective for Diagnostic
Radiopharmaceuticals by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East and Latin America
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) II-107


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Contrast Media Market to Witness Slow but Steady Growth III-1
Table 44: US Contrast Media Market by Leading Players
(2013): Percentage Dollar Share Breakdown for Bayer,
Bracco, GE Healthcare, Mallinckrodt and Others (includes
corresponding Graph/Chart) III-2
Diagnostic Radiopharmaceuticals to Drive Future Growth III-2
Table 45: The US Diagnostic Radiopharmaceutical Agents
Market (2012): Percentage Share Breakdown of Procedure
Volume by Imaging Procedure - SPECT and PET (includes
corresponding Graph/Chart) III-3

Table 46: US Market for Diagnostic Radiopharmaceuticals
Agents (2012): Percentage Share Breakdown of Value Sales
for Cardiology and Non-Cardiology Applications (includes
corresponding Graph/Chart) III-3

Table 47: US Market for Cardiology Diagnostic
Radiopharmaceuticals (2010): Percentage Share Breakdown of
SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume
by Imaging Agent - Cardiolite, Myoview, Thallium, and
Sestamibi (includes corresponding Graph/Chart) III-3
Recession Impact in Retrospect III-4
Growth Stimulants in a Nut Shell III-4
Demographic Changes Offer Growth Opportunities III-5
Table 48: North American Aging Population by Age Group:
1975-2050 (includes corresponding Graph/Chart) III-5
Dynamics of Pricing III-6
Key Trends and Issues III-6
Expanding Applications to Stimulate Growth in Dx
Radiopharmaceuticals Market III-6
New Oncology, Neurology Agents to Boost Growth III-6
Table 49: US Market for Non-Cardiology Diagnostic
Radiopharmaceuticals Agents (2012): Percentage Share
Breakdown of Value Sales for Oncology and Non-Oncology
Applications (includes corresponding Graph/Chart) III-7
Managing Alzheimer’s Opens New Avenues for Imaging Agents III-7
List of FDA Approved Alzheimer's Diagnostic Imaging Agents III-8
Alzheimer’s Stats III-9
Table 50: Alzheimer’s Prevalence in the US: As a
Percentage of Population by Age-Group (includes
corresponding Graph/Chart) III-9

Table 51: Alzheimer’s Prevalence in the US by State: 2014 and
2025 (includes corresponding Graph/Chart) III-9
Nuclear Cardiology Products Drive Diagnostic
Radiopharmaceuticals Market III-10
Cardiovascular Imaging to Lead Volume Growth III-10
PET Procedures in the US on Rise III-10
Table 52: US PET Market by Leading Players (2013):
Percentage Market Share Breakdown of Value Sales for GE
Healthcare, Philips Healthcare, Siemens Healthcare and
Others (includes corresponding Graph/Chart) III-11
Growing Adoption of SPECT/CT III-11
Rising Incidence of Cancer - A Major Growth Driver III-11
Table 53: US Cancer Fatalities by Gender (2014):
Percentage Share Breakdown of No. of Deaths for Men and
Women (includes corresponding Graph/Chart) III-11

Table 54: New Cancer Cases by Gender and Affected Site in
the US (2013) III-12
Isotope Shortage Leads to Dependence on Imports III-13
DOE’s Flawed Isotope Program Adds to the Woe III-13
US Fluorodeoxyglucose (FDG) Market: An Overview III-13
Table 55: US FDG Market by Procedure Type (2012):
Percentage Share Breakdown of Procedure Volume for
Oncology, Neurology, and Cardiology (includes
corresponding Graph/Chart) III-14
Competitive Analysis - Imaging Market III-14
Reimbursement Issues III-14
Medicare Payment Settings for Contrast Agents and
Radiopharmaceuticals III-15
Contrast Agents and Diagnostic Radiopharmaceuticals
Bundled As Supplies III-15
Implications of Reimbursement Changes III-16
Magnetic Resonance Imaging III-16
CMS’ Rules Change Cuts Down Technical Component of MRI
Reimbursement III-17
Table 56: A Comparison of Medicare Reimbursement Rates
for Upper and Lower Extremity MRI Examinations for 2012
and 2013 III-17

Table 57: MRI Reimbursement Changes: CPT Codes for MRI
and MR Angiography (MRA) and Payment Rates for 2013 and
2014 III-18
The Fallout of ATRA on MRI Examination Trends III-19
Regulatory Environment III-19
Provisions Regarding Off-Label Usage of Contrast Media III-20
Product Launches/Approvals III-20
Strategic Corporate Developments III-24
Key Players III-25
B.Market Analytics III-27
Table 58: US Recent Past, Current and Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-27

Table 59: US Historic Review for Imaging Agents by Product
Segment - Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-28

Table 60: US 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-29

2. CANADA III-30
A.Market Analysis III-30
Current and Future Analysis III-30
An Overview of Medical Imaging Market III-30
Table 61: Percentage Distribution of Canadian Population
by Age Group: 2012 (includes corresponding Graph/Chart) III-31
Canadian Scientists Discover Remedy for Isotope Shortages III-31
Regulatory and Legal Restrictions III-31
Strategic Corporate Development III-32
B.Market Analytics III-33
Table 62: Canadian Recent Past, Current and Future Analysis
for Imaging Agents by Product Segment - Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2013 through
2020 (includes corresponding Graph/Chart) III-33

Table 63: Canadian Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-34

Table 64: Canadian 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-35

3. JAPAN III-36
A.Market Analysis III-36
Current and Future Analysis III-36
Demographics Drive Market Growth III-36
Table 65: Japanese Population by Age Group (2012) (
includes corresponding Graph/Chart) III-37
Table 66: Japanese 65+ Years Population: 1950-2010
(includes corresponding Graph/Chart) III-37
Number of Nuclear Medicine Procedures on the Rise III-37
Reimbursement Issues III-38
Strategic Corporate Development III-38
Key Players III-38
B.Market Analytics III-40
Table 67: Japanese Recent Past, Current and Future Analysis
for Imaging Agents by Product Segment - Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2013 through
2020 (includes corresponding Graph/Chart) III-40

Table 68: Japanese Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-41

Table 69: Japanese 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-42

4. EUROPE III-43
A.Market Analysis III-43
Outlook III-43
Debt Crisis in Europe Affects Healthcare Industry III-43
European Healthcare System: In a State of Transition? III-44
Nuclear Medicine Imaging Equipment Market: An Overview III-44
Table 70: European Installed Base for Diagnostic Imaging
Equipment by Modality (2013): Percentage Share Breakdown of
Volume Installations for SPECT, PET/CT, SPECT/CT, Planar,
Cardiac SPECT, and PET/MR (includes corresponding
Graph/Chart) III-44
Cancer: A Major Driver for Diagnostic Radiopharmaceuticals III-45
Table 71: Cancer Incidence in Europe by Site: 2012 (in
Thousands) (includes corresponding Graph/Chart) III-45
Ageing Demography - An Opportunity Indicator III-46
Table 72: Population Breakup by Age Group for Select
European Countries: 2011 (as a Percentage of Total
Population) (includes corresponding Graph/Chart) III-46
Reimbursement III-47
Outsourcing of Imaging Diagnostics III-47
Distribution Structure III-47
Direct Sales III-47
License Agreements III-47
Distribution Agreements III-48
A Price Sensitive Market III-48
Macro Environment III-48
Germany III-48
France III-48
Spain and Italy III-48
Scandinavia III-49
B.Market Analytics III-50
Table 73: European Recent Past, Current and Future Analysis
for Imaging Agents by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-50

Table 74: European Historic Review for Imaging Agents by
Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2006
through 2012 (includes corresponding Graph/Chart) III-51

Table 75: European 15-Year Perspective for Imaging Agents by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-52

Table 76: European Recent Past, Current and Future Analysis
for Imaging Agents by Product Segment - Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2013 through
2020 (includes corresponding Graph/Chart) III-53

Table 77: European Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-54

Table 78: European 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-55

4a. FRANCE III-56
A.Market Analysis III-56
Current and Future Analysis III-56
Growth Stimulants III-56
Guerbet Group - A Key Player III-56
B.Market Analytics III-57
Table 79: French Recent Past, Current and Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-57

Table 80: French Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-58

Table 81: French 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-59

4b. GERMANY III-60
A.Market Analysis III-60
Current and Future Analysis III-60
Bayer Healthcare Pharmaceuticals - A Key Player III-60
B.Market Analytics III-61
Table 82: German Recent Past, Current and Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-61

Table 83: German Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-62

Table 84: German 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-63

4c. ITALY III-64
A.Market Analysis III-64
Current and Future Analysis III-64
B.Market Analytics III-65
Table 85: Italian Recent Past, Current and Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-65

Table 86: Italian Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-66

Table 87: Italian 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-67

4d. THE UNITED KINGDOM III-68
A.Market Analysis III-68
Current and Future Analysis III-68
Strategic Corporate Development III-68
Key Players III-68
B.Market Analytics III-70
Table 88: UK Recent Past, Current and Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-70

Table 89: UK Historic Review for Imaging Agents by Product
Segment - Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-71

Table 90: UK 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-72

4e. SPAIN III-73
A.Market Analysis III-73
Current and Future Analysis III-73
B.Market Analytics III-74
Table 91: Spanish Recent Past, Current and Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-74

Table 92: Spanish Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-75

Table 93: Spanish 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-76

4f. RUSSIA III-77
A.Market Analysis III-77
Current and Future Analysis III-77
B.Market Analytics III-78
Table 94: Russian Recent Past, Current and Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-78

Table 95: Russian Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-79

Table 96: Russian 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2006, 2014 and 2020
(includes corresponding Graph/Chart) III-80

4g. REST OF EUROPE III-81
A.Market Analysis III-81
Current and Future Analysis III-81
Product Approval III-81
Strategic Corporate Developments III-81
Mallinckrodt Pharmaceuticals (Ireland) - A Key Player III-82
B.Market Analytics III-83
Table 97: Rest of Europe Recent Past, Current and Future
Analysis for Imaging Agents by Product Segment - Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2013 through
2020 (includes corresponding Graph/Chart) III-83

Table 98: Rest of Europe Historic Review for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-84

Table 99: Rest of Europe 15-Year Perspective for Imaging
Agents by Product Segment - Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) III-85

5. ASIA-PACIFIC III-86
A.Market Analysis III-86
Current and Future Analysis III-86
Healthcare Spending in Asia-Pacific: On the Rise III-86
Aging Populace - Potential Opportunities III-86
Table 100: Over 65 Years Individuals as % of Total
Population in Select Asian Countries (includes
corresponding Graph/Chart) III-87
India and China Offer Significant Growth Opportunities III-87
MRI Market in Asia III-87
B.Market Analytics III-89
Table 101: Asia-Pacific Recent Past, Current and Future
Analysis for Imaging Agents by Geographic Region - China,
India and Rest of Asia-Pacific Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2013 through 2020 (includes corresponding Graph/Chart) III-89

Table 102: Asia-Pacific Historic Review for Imaging Agents
by Geographic Region - China, India and Rest of Asia-Pacific
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-90

Table 103: Asia-Pacific 15-Year Perspective for Imaging
Agents by Geographic Region - Percentage Breakdown of Dollar
Sales for China, India and Rest of Asia-Pacific Markets for
Years 2006, 2014 and 2020 (includes corresponding Graph/Chart) III-91

Table 104: Asia-Pacific Recent Past, Current and Future
Analysis for Imaging Agents by Product Segment - Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2013 through
2020 (includes corresponding Graph/Chart) III-92

Table 105: Asia-Pacific Historic Review for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2006 through 2012 (includes corresponding
Graph/Chart) III-93

Table 106: Asia-Pacific 15-Year Perspective for Imaging
Agents by Product Segment - Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for Years 2006, 2014 and
2020 (includes corresponding Graph/Chart) III-94

5a. CHINA III-95
A.Market Analysis III-95
Current and Future Analysis III-95
Medical Imaging Equipment Market - An Overview III-95
Increasing Expenditure on Healthcare Sector III-95
B.Market Analytics III-96
Table 107: Chinese Recent Past, Current and Future Analysis
for Imaging Agents by Product Segment - Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2013 through
2020 (includes corresponding Graph/Chart) III-96

Table 108: Chinese Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-97

Table 109: Chinese 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

The 2014 World%s Leading Diagnostic Imaging Companies

The 2014 World%s Leading Diagnostic Imaging Companies

  • $ 14 500
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $14,500.  Individual company assessments $2,450.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...

Future Horizons and Growth Strategies in the Global Diagnostic Imaging Market 2014: Strategic Assessments of Leading Suppliers

Future Horizons and Growth Strategies in the Global Diagnostic Imaging Market 2014: Strategic Assessments of Leading Suppliers

  • $ 14 500
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $14,500.  Individual company assessments $2,450.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...

The 2014 Global Ultrasound Market: Strategic Assessments of Leading Suppliers

The 2014 Global Ultrasound Market: Strategic Assessments of Leading Suppliers

  • $ 12 500
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $12,500.  Individual company assessments $1,850.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.